Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jul 1;17(4):192-198.
doi: 10.1097/COH.0000000000000735.

The future of long-acting agents for preexposure prophylaxis

Charles Flexner  1   2
Affiliations
Review

The future of long-acting agents for preexposure prophylaxis

Charles Flexner. Curr Opin HIV AIDS. .

Abstract

Purpose of review: The main reason for the failure of oral preexposure prophylaxis (PrEP) regimens for HIV is poor adherence. Intramuscular cabotegravir was recently approved for PrEP, and a number of other long-acting antiretroviral formulations and products are currently in clinical development. This includes subcutaneous and intravenous injections, implants, and microarray (microneedle) patches, as well as extended duration oral drugs. The success and future uptake of these products will depend on a variety of factors.

Recent findings: Long-acting delivery of antiretroviral agents for PrEP confers significant advantages over short-acting oral delivery. This is exemplified by the superior efficacy of intramuscular cabotegravir given every eight weeks as compared to daily oral co-formulated tenofovir disoproxil fumarate and emtricitabine. There is also evidence for PrEP efficacy for a broadly neutralizing monoclonal antibody given intravenously every eight weeks. One of the leading candidates for long-acting PrEP, islatravir, was being studied as a monthly oral drug or a nonerodable subcutaneous implant inserted for up to 12 months. However, clinical studies of this agent were put on hold in late 2021 because of unanticipated lymphopenia.

Summary: Long-acting antiretroviral products have substantial promise for PrEP and have particular advantages over daily oral drugs based mainly on improved adherence. However, there are barriers to further uptake that include the need for more intensive interaction with systems of healthcare delivery, greater expense and complexity of implementation, and unexpected long-term toxicities.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest

C.F. reports serving as a paid consultant for Gilead Sciences, Janssen Pharmaceuticals, Merck Laboratories, and ViiV Healthcare.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Landovitz RJ, Donnell D, Clement ME, Hanscom B, Cottle L, Coelho L, et al. Cabotegravir for HIV prevention in cisgender men and transgender women. N Engl J Med. 2021; 385(7): 595–608. doi: 10.1056/NEJMoa2101016.

      **This is the first large randomized trial to demonstrate the superiority of injectable cabotegravir PrEP over a standard one-pill once-a-day regimen.

    1. Flexner C, Owen A, Siccardi M, Swindells S. Long-acting drugs and formulations for the treatment and prevention of HIV. Int J Antimicrob Agents 2021. Jan;57(1):106220. doi: 10.1016/j.ijantimicag.2020.106220.

      **This is a recent comprehensive review of long-acting drug delivery technologies in development for HIV.

    1. Weld ED, Rana MS, Dallas RH, Camacho-Gonzalez AF, Ryscavage P, Gaur AH, et al. Interest of youth living with HIV in long-acting antiretrovirals. J Acq Immune Defic Syndr 2019; 80:190–197. - PMC - PubMed
    1. Rajoli RKR, Curley P, Chiong J, Back DJ, Flexner C, Owen A, Siccardi M. Predicting drug-drug interactions between rifampicin and long-acting cabotegravir and rilpivirine using PBPK modelling. J Infect Dis 2019; 219: 1735–1742. doi: 10.1093/infdis/jiy726. - DOI - PMC - PubMed
    1. Nachman S, Townsend CL, Abrams EJ, Archary M, Capparelli E, Clayden P, et al. Long acting/extended release antiretroviral products for HIV treatment and prevention in infants, children, adolescents and pregnant and breastfeeding women: knowledge gaps and research priorities. Lancet HIV 2019; 2019. Aug; 6: e552–e558. doi: 10.1016/S2352-3018(19)30147-X. - DOI - PMC - PubMed

Publication types

MeSH terms